» Articles » PMID: 38167855

Factors Associated with Late Initiation of Antiretroviral Therapy in Iran's HIV/AIDS Surveillance Data

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jan 3
PMID 38167855
Authors
Affiliations
Soon will be listed here.
Abstract

Early initiation of Antiretroviral Treatment (ART) in HIV patients is essential for effectively suppressing the viral load and prognosis. This study utilized National HIV/AIDS Surveillance Data in Iran to identify factors associated factors with the duration to initiate ART. This hybrid cross-sectional historical cohort study was conducted on Iran's National HIV/AIDS Surveillance Data from 2001 to 2019. Sociodemographic characteristics, route of transmission, HIV diagnosis date, and ART initiation date were collected. Multivariable linear and quantile regression models were employed to analyze the duration to initiate ART by considering predictor variables. This study included 17,062 patients (mean age 34.14 ± 10.77 years, 69.49% males). Multivariate quantile regression coefficients varied across different distributions of the dependent variable (i.e., duration to initiate ART) for several independent variables. Generally, male gender, injecting drug use (IDU), and having an HIV-positive spouse were significantly associated with an increased duration to initiate ART (p < 0.05). However, a significant decrease was observed in older patients, those with a university level education, men who had sex with men (MSM), and patients diagnosed after 2016 (p < 0.05). Despite improvements in the duration to initiate ART after implementing the WHO's 2016 program in Iran, various sociodemographic groups were still vulnerable to delayed ART initiation in the region. Therefore, programs including early testing, early ART initiation, active care, educational and cultural interventions, and appropriate incentives are required for these groups.

Citing Articles

Temporal trends from HIV diagnosis to ART initiation among adults living with HIV in the Asia-Pacific (2013-2023).

Vu T, Rupasinghe D, Khol V, Chaiwarith R, Tanuma J, Kumarasamy N AIDS Res Ther. 2025; 22(1):29.

PMID: 40038791 PMC: 11881487. DOI: 10.1186/s12981-025-00718-8.


Design of multivalent-epitope vaccine models directed toward the world's population against HIV-Gag polyprotein: Reverse vaccinology and immunoinformatics.

Hashempour A, Khodadad N, Bemani P, Ghasemi Y, Akbarinia S, Bordbari R PLoS One. 2024; 19(9):e0306559.

PMID: 39331650 PMC: 11432917. DOI: 10.1371/journal.pone.0306559.

References
1.
Joulaei H, Shooshtarian S, Dianatinasab M . Is UNAIDS 90-90-90 target a Dream or a Reality for Middle East and North Africa Region on Ending the AIDS Epidemic? A Review Study. AIDS Rev. 2018; 20(2):83-93. DOI: 10.24875/AIDSRev.M18000020. View

2.
Cescon A, Patterson S, Davey C, Ding E, Raboud J, Chan K . Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. J Int AIDS Soc. 2015; 18:20024. PMC: 4595457. DOI: 10.7448/IAS.18.1.20024. View

3.
Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O . The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013; 57(7):1038-47. DOI: 10.1093/cid/cit423. View

4.
Poorolajal J, Hooshmand E, Mahjub H, Esmailnasab N, Jenabi E . Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health. 2016; 139:3-12. DOI: 10.1016/j.puhe.2016.05.004. View

5.
Agaba P, Meloni S, Sule H, Agbaji O, Ekeh P, Job G . Patients who present late to HIV care and associated risk factors in Nigeria. HIV Med. 2014; 15(7):396-405. DOI: 10.1111/hiv.12125. View